Hims & Hers (HIMS) Form 144: Proposed Sale of 145,000 Shares

Form 144 filed for Hims & Hers Health, Inc. (HIMS) discloses a proposed sale of 145,000 shares of common stock through Goldman Sachs & Co. LLC on 09/15/2025 with an indicated aggregate market value of $7,824,200.

Rhea-AI Filing Summary

Form 144 filed for Hims & Hers Health, Inc. (HIMS) discloses a proposed sale of 145,000 shares of common stock through Goldman Sachs & Co. LLC on 09/15/2025 with an indicated aggregate market value of $7,824,200. The filing lists the securities to be sold as consisting of previously granted compensation instruments, including multiple restricted stock unit grants dated 06/15/2024, 09/15/2024 and several stock option cashless exercises dated 02/24/2022 through 08/24/2025. The filer also reported a series of sales by Oluyemi Okupe in June–August 2025 (examples: 23,107 shares on 06/23/2025; 11,581 shares on 07/07/2025 and additional July/August trades) with reported gross proceeds for each transaction. The notice includes the required signature representation regarding material nonpublic information.

Positive

• Detailed disclosure of the source of the shares (RSUs and option exercises) and broker information (Goldman Sachs & Co. LLC)
• Filer attests there is no known undisclosed material adverse information, as required by the form

Negative

• Insider intends to sell 145,000 shares of common stock with an aggregate market value of $7,824,200
• Multiple recent sales by the named individual are reported for June–August 2025, indicating ongoing insider monetization

Insights

Financial Analyst

TL;DR: Routine insider sale notice driven by compensation-related holdings; no operating results disclosed.

The filing is a standard Rule 144 notice showing an intended sale of 145,000 common shares via Goldman Sachs with an aggregate quoted market value of $7,824,200, and details the acquisition sources as RSUs and cashless-option exercises. This is a disclosure of liquidity activity by an insider rather than operating performance or capital-structure change. Investors should view this as insider monetization of compensation rather than a corporate action affecting cash flows or guidance, noting also multiple recent small sales by the named individual in June–August 2025.

Corporate Governance Expert

TL;DR: Filing complies with Rule 144 disclosure requirements; shows routine harvesting of compensation awards.

The document provides the requisite broker, intended sale date, and detailed acquisition history (RSUs and option exercises), which supports transparency and compliance with insider-sale rules. The signer affirms absence of undisclosed material information. As a governance matter, the filing is routine and does not itself indicate misconduct or a change in control, but it documents insider liquidity events that shareholders may monitor for pattern or frequency.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 for HIMS announce?

The Form 144 announces a proposed sale of 145,000 HIMS common shares through Goldman Sachs on 09/15/2025, with an aggregate market value of $7,824,200.

What types of securities were acquired that are being sold?

The filing shows the shares originated from restricted stock units (RSUs) and stock option cashless exercises acquired between 02/24/2022 and 08/24/2025.

Were there recent insider sales by the same person?

Yes. The filing lists sales by Oluyemi Okupe in 2025, including 23,107 shares on 06/23/2025 and several 11,581-share trades in July and August 2025, with reported gross proceeds for each.

Who is the broker handling the proposed sale?

The proposed sale is to be handled by Goldman Sachs & Co. LLC, 200 West Street, New York, NY.

Does the filing disclose any material nonpublic information about HIMS operations?

No. By signing the notice the filer represents they do not know of any undisclosed material adverse information; the filing contains no operational or financial results.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 09/15/2025 - 06:35 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001907056
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Hims & Hers Health, Inc.
SEC File Number	001-38986
Address of Issuer	2269 Chestnut Street Suite 523 San Francisco CALIFORNIA 94123
Phone	1-415-851-0195
Name of Person for Whose Account the Securities are To Be Sold	Oluyemi Okupe
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	145000	7824200	217641958	09/15/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/15/2024	Acquired as compensation -- Restricted Stock Units	Issuer			9088	06/15/2024	Compensation
Common	06/15/2024	Acquired as compensation -- Restricted Stock Units	Issuer			8223	06/15/2024	Compensation
Common	09/15/2024	Acquired as compensation -- Restricted Stock Units	Issuer			7042	09/15/2024	Compensation
Common	09/15/2024	Acquired as compensation -- Restricted Stock Units	Issuer			300	09/15/2024	Compensation
Common	09/15/2024	Acquired as compensation -- Restricted Stock Units	Issuer			10347	09/15/2024	Compensation
Common	02/24/2022	Acquired as compensation -- Stock Options	Issuer			25000	02/24/2022	Compensation -- Cashless exercise / same-day sale
Common	05/24/2025	Acquired as compensation -- Stock Options	Issuer			21486	05/24/2025	Compensation -- Cashless exercise / same-day sale
Common	06/24/2025	Acquired as compensation -- Stock Options	Issuer			21486	06/24/2025	Compensation -- Cashless exercise / same-day sale
Common	07/24/2025	Acquired as compensation -- Stock Options	Issuer			21485	07/24/2025	Compensation -- Cashless exercise / same-day sale
Common	08/24/2025	Acquired as compensation -- Stock Options	Issuer			20543	08/24/2025	Compensation -- Cashless exercise / same-day sale

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	06/23/2025	23107	1091767
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	07/07/2025	11581	540498.84
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	07/14/2025	11581	552417.98
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	08/13/2025	11581	556419.19
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	08/26/2025	11581	505968.38

144: Remarks and Signature

Remarks	The sales of shares set forth herein are made in connection with a selling plan dated 5/21/2025, that is intended to comply with Rule 10b5-1(c).
Date of Notice	09/15/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	05/21/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Goldman Sachs & Co. LLC on behalf of Oluyemi Okupe
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)